Liwasag, Baby Boy .
HRN: 23-07-60 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/03/2023
MUPIROCIN 2%, 15G (TUBE)
06/03/2023
06/08/2023
TOPICAL OU
Thinly
Bid
Skin Infection
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes